Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Bonella, I. Campo, C. H. M. van Moorsel, M. Griese, J. C. Grutters, U. Costabel, M. Luisetti (Essen, Munich, Germany; Pavia, Italy; Nieuwegein, Netherlands). European pulmonary alveolar proteinosis network (EuPAPNet): Results from biomarkers´ investigation. Eur Respir J 2014; 44: Suppl. 58, 1736

Member's Comments

No comment yet.

Related content which might interest you: Clinical features of four children with pulmonary alveolar proteinosis Source: International Congress 2014 – ILDs 5 Year: 2014 Acute exacerbation of idiopathic pulmonary fibrosis: Analysis in a post-marketing surveillance of pirfenidone Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Early effect of whole lung lavage (WLL) on surfactant homeostasis in pulmonary alveolar proteinosis (PAP) Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Periostin, a matrix protein, is a novel biomarker for idiopathic interstitial pneumonias Source: International Congress 2014 – IPF and surroundings Year: 2014 Clinical features and prognosis of 108 patients with lymphangioleiomyomatosis Source: International Congress 2014 – ILDs: diagnostic and prognostic investigations Year: 2014 Prognostic influence of comorbidities in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2014 – ILDs 2 Year: 2014 Aetiological panorama in the diagnosis of interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Evolution of an interstitial lung disease MDT: 5.5 years of data Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Pregnancy course in patients with interstitial lung diseases Source: International Congress 2014 – ILDs 5 Year: 2014 Pulmonary distribution and localization of pirfenidone in animal models of IPF by MS/MS Source: International Congress 2014 – ILDs 4 Year: 2014 Pulmonary manifestations in rheumatoid arthritis: A hospital based descriptive study Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Surfactant protein B proforms as potential new biomarkers for idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Intraindividual response to treatment with pirfenidone in two independent European IPF cohorts Source: International Congress 2014 – ILDs 2 Year: 2014 Cystic lung disease with pulmonary amyloidosis: Analysis of 21 patients Source: International Congress 2014 – ILDs: connective tissue disease Year: 2014 Annual changes in pulmonary function are independent prognostic factors for the patients with chronic hypersensitivity pneumonia Source: International Congress 2014 – ILDs 3 Year: 2014 Treatment of IPF with inhaled IFN-gamma; planning for a clinical trial Source: International Congress 2014 – ILDs 3 Year: 2014 Cryptogenic organising pneumonia focusing on its prognostic determinants Source: International Congress 2014 – ILDs 4 Year: 2014 Asbestos-related disorders (ARDs): Influence of pleural plaques and pulmonary fibrosis due to asbestos exposure on lung function decline (LFD) Source: International Congress 2014 – ILDs 5 Year: 2014 Mucus production, lung inflammation and functional decay in IPF Source: International Congress 2014 – ILDs: pathogenesis and clinical features Year: 2014 Six-minute-walk test parameters in the prognostic evaluation of fibrotic lung diseases Source: International Congress 2014 – ILDs 4 Year: 2014